Do now
Build the care foundation
Blood pressure management, kidney-function follow-up, imaging and risk assessment, medication review, and a plan for complications.
What helps now, and what is still being studied
Start with blood pressure control and progression-risk assessment. Tolvaptan can slow decline in selected adults at risk of rapid progression, but it is not appropriate for everyone.
Evidence reviewed: August 24, 2026
On this page
Discuss with your nephrologist
Consider tolvaptan
For adults at risk of rapid progression, the decision depends on expected benefit, liver monitoring, contraindications, and aquaretic side effects.
Watch, do not self-treat
Follow emerging options
Promising signals and active trials are not established treatment until meaningful human outcomes are confirmed.
What helps now
Tolvaptan Proven
Best-supported disease-modifying therapy in selected rapid progressors.
KDIGO supports initiation in adults at risk of rapid progression (with strict LFT monitoring and contraindication screening)
Blood pressure control Proven
Core progression/safety strategy in guideline care.
KDIGO target details now extracted (younger CKD G1-G2 intensive home-BP target when tolerated; older/CKD G3-G5 standardized SBP target <120)
Low sodium intake Proven
Strong supportive strategy with guideline backing.
KDIGO links lower osmolar intake with reduced aquaretic burden during tolvaptan use
Evidence hierarchy
What may slow progression
These labels separate available care from research signals. They do not decide what is safe or useful for one person.
Established now
Tolvaptan for appropriate rapid progressors, blood pressure control, and low-sodium supportive care.
Being studied
- Dapagliflozin add-on to tolvaptan: Early positive human signal but not practice-changing yet.
- SGLT2 inhibitors in non-diabetic ADPKD: Human evidence remains insufficient and is not practice-changing.
Not supported for routine use
- GLPG2737 (CFTR inhibitor): Negative phase-2a human readout; not a supported disease-modifying path.
- Metformin (non-diabetes ADPKD): Current human randomized evidence is net negative/uncertain for disease-modification.
How to judge treatment claims
- Meaningful human outcomes matter more than a laboratory mechanism.
- A trial being active does not mean the treatment works.
- Small or short studies can justify more research without changing standard care.
- Your progression risk, kidney function, other conditions, and preferences affect treatment decisions.
Next useful step
Prepare for your appointment
Use a short question list to turn general information into a care plan built around your risk and priorities.
Questions for your doctor Medical Disclaimer
This resource provides educational information about ADPKD and is not a substitute for professional medical advice. Always discuss treatment decisions, symptoms, and health concerns with your nephrologist or primary care physician before making any changes.